Don’t Be a Daredevil When Retrofitting Your Facility, Part 2

In Part 1 of “Don’t Be a Daredevil When Retrofitting Your Facility,” I laid the groundwork covering why a disciplined approach needs to be taken when repurposing rooms, particularly when new management is taking a different approach in an existing facility. 

In this Part 2, I present a few of the retrofitting-gone-wrong examples I have seen in my years in the field. Each of these examples happened in established, well-known companies that, when faced with the need to repurpose a room, decided to daredevil it a bit instead of going back to a detailed blueprint. 

In example number one, a company decided to take an active tableting room out of service and utilize it as a clean parts storage area. They conducted a risk assessment, which found that the storage room presented less of a risk to the product than as an active tableting room. The firm felt that the room air supply filtration and active air changes were well in excess of that needed for a storage room, choosing to leave that functionality in place to save time. 

The company failed to recognize, however, that the filling room was designed for negative pressure to the hallway due to potential dust generation of the tableting operation. As a clean parts storage room, the proper design is to have the room be positive pressure to the hallway to prevent migration of particulate into the storage space.

In another example, a room originally designed as a small parts washroom was repurposed to wash larger equipment, including portable tanks. Engineers focused on the plumbing availability in the space, concluding that the drains could handle the larger quantity of water used as the primary utility in a wash bay, but they failed to consider the impact to other utilities within the space. The Air Handling Units (AHU), for example, did not have the capacity to remove the excess heat and moisture generated by the new washing processes and failed to keep the room in a state of control during use, impacting nearby rooms as well. 

Secondly, the AHUs did not have the ability to keep the moisture in the vapor phase as the uninsulated duct work passed through non-temperature-controlled mechanical spaces prior to venting outside. While it is not uncommon for exhaust ductwork to remain uninsulated as there is no energy efficiency to be reclaimed, in this case, the moisture collected on the ductwork, dripped back down the duct, and leaked into interstitial and mechanical spaces. Needless to say, a mold problem ensued.

In another case, a firm decided to expand its production area because of an expected increase in manufacturing orders. It correctly isolated construction zones from the current manufacturing areas and proceeded to build and validate the new processing rooms. When the new processing rooms were put into service, it put an increased load on the existing preparation areas. As a result, more supplies were needed in the preparations room, and work in process was also being accumulated. Operators were unaware that the additional materials were disrupting the airflow in the room due to partial obstruction of low wall returns. The airflow disruption negatively affected the environmental monitoring results of the room, leading to high viable and nonviable particle counts. The engineers failed to account for the impact on the other production spaces during the planning for their new production rooms. While the equipment was physically capable of handling the increased capacity, the staging before and after processing was not considered. This led to employees “making do”—violating the operating principles of the space.

In sum, retrofitting existing spaces is possible, and sometimes necessary to maximize the effective use of existing infrastructure, but these changes must be proactively assessed and planned carefully in advance of product line consolidation. Only then can we ensure that the facility is purpose-built and will not become a patchwork activity that regulators will refuse to approve.


QxP Vice President Bob Ferer is a 30-year veteran in pharma. Prior to joining QxP, Bob worked with Sanofi Pasteur on a building / process train renovation. His role for Sanofi was to support the team from a compliance and regulatory aspect for the testing, qualification, and validation for all critical utilities, equipment, systems, and processes. Bob’s experience and insights have been very valuable to QxP clients.  

Pharmaceutical Industry Trends for 2024 So Far

Christine Feaster
April 24, 2024

Decoding the Technical Transfer Process in Biotech Manufacturing

Sarah Boynton
April 23, 2024

Quality Executive Partners - IACET Accreditation

Ken Mead
April 9, 2024

Coaching and Correcting: A Focus on Behavior Over Blame

Sarah Boynton
November 1, 2023

The Importance of Roles and Responsibilities in Biotech Manufacturing & Human Error Prevention

Sarah Boynton
October 26, 2023

Remote cGMP Inspections and AI in Drug Manufacturing

Michelle Fishburne
October 11, 2023

4 Best Practices for Effective Investigation into Deviations

Sarah Boynton
September 19, 2023

The Art of Viral Vector Manufacturing: 4 Essential Controls to Prevent Cross-Contamination

Sarah Boynton
September 13, 2023

Practicing Risk Acceptance

Mark Roache
August 28, 2023

Annex 1 – Can we all take a deep breath now?

Vanessa Figueroa
August 24, 2023

In Cell and Gene, Good Science is Necessary, But Not Sufficient

Mark Roache
August 21, 2023

6 Ways To Achieve Manufacturing Audit And Inspection Readiness

Sarah Boynton
August 14, 2023

Experience is What You Get Just After You Needed It, Part 2

Mark Roache
August 10, 2023

Experience is What You Get Just After You Needed It, Part 1

Mark Roache
August 10, 2023

Sterility Assurance Matters to This ONE

Greg Gibb
August 8, 2023

Enhancing Quality and Safety: 3 Essential Human Error Prevention Tools for cGMP Manufacturing

Sarah Boynton
August 3, 2023

Asia-Pacific Happenings: Samsung Bioepis Implements QxP Virtuosi®

Michelle Fishburne
August 2, 2023

CDMOs – Selecting the Right One for Each Manufacturing Stage

Christine Feaster
July 24, 2023

3 Types of Human Error and Potential CAPAs to Prevent Them

Sarah Boynton
July 20, 2023

Drug Shortages: Causes & Solutions

Christine Feaster
July 10, 2023

The 5 Questions You Need to Ask After a Human Error Event Occurs

Sarah Boynton
July 5, 2023

Understanding How Adults Learn

Mike Levitt
June 30, 2023

Annex 1 and Ensuring Filling Technologies Fit the Need

Natasha Howard
June 21, 2023

How to Solve Pharma’s Skilled Workforce Deficit

Jeff Roy
June 20, 2023

ChatGPT Told Me AI is “Imperative” in Pharma Manufacturing

No items found.
June 18, 2023

Get Ready: FDORA’s Unannounced Foreign Inspection Pilot Program is On!

Crystal Mersh
June 6, 2023

Nitrosamines Impurity Challenges

Christine Feaster
June 2, 2023

All You Need to Know About Contamination Control Strategies, Parts 1 and 2

No items found.
June 1, 2023

When is ISO 8 Not ISO 8?

Bob Ferer
May 30, 2023

Cost Of Quality: Worth Every Cent In Bio/Pharmaceutical Manufacturing

Crystal Mersh
May 24, 2023

Pharmaceutical Quality is NOT a Spectator Sport

Mike Levitt
May 22, 2023

The Six Keys for Effective Deviation Investigators

Mike Levitt
May 18, 2023

There Has to be a Better Way to Train

Tyler DeWitt, Ph.D.
May 15, 2023

Cell and Gene: Article Series on CGT’s Key Drivers

Mark Roache
May 8, 2023

Bacterial Endotoxin Testing is on the Move

Christine Feaster
May 5, 2023

Top 20 Pharma Company Chooses QxP Virtuosi® Platform

Vanessa Figueroa
May 3, 2023

Crystal Clear: Controls Are Not Enough

Crystal Mersh
April 22, 2023

Myth #1: Complying with Regulations and Product Specifications

Brian Duncan
April 20, 2023

Myth #2: Proactively Remediating Bad Inspection Outcomes: What’s the benefit?

Brian Duncan
April 20, 2023

Is it Time to Outsource Internal Auditing?

Mike Levitt
April 18, 2023

Quality is Number One, Even When Trying to Address Supply Chain Issues

Christine Feaster
April 14, 2023

Don’t Be a Daredevil When Retrofitting Your Facility, Part 1

Bob Ferer
April 10, 2023